DelveInsight launched a new report on “Lupus Nephritis – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Lupus Nephritis – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the facts of the report

1. As per DelveInsight analysis, the United Sates accounted for the maximum number of LN patients with 134,190 cases in 2017.

2. As per DelveInsight analysis, Italy accounted for 134,190 LN patients in 2017.

3. DelveInsight estimates, in 2017, Proteinuria associated with LN cases were found in all of the diagnosed cases, while second common manifestation in LN was microscopic hematuria with 85,882 cases (80%).

4. As per DelveInsight’s estimates, total Prevalent population of Lupus Nephritis in the 7 major markets was 190,819 in 2017,

Key benefits of the report

1. Lupus Nephritis market report covers a descriptive overview and comprehensive insight of the Lupus Nephritis epidemiology and Lupus Nephritis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Lupus Nephritis market report provides insights on the current and emerging therapies.
3. Lupus Nephritis market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. Lupus Nephritis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Lupus Nephritis market.

Request for sample pages : https://delveinsight.com/sample-request/lupus-nephritis-market

 

“According to Delveinsight, Market Size of Lupus Nephritis (LN) in the 7MM was found to be $1360million in 2017.”

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease and is the most common form of lupus that can affect multiple tissues and organs. The disease is being characterized by the production of antibodies to components of the cell nucleus in association with a diverse array of clinical manifestations.

The primary pathological findings in patients with SLE include inflammation, vasculitis, immune complex deposition, and vasculopathy.

Lupus nephritis (LN) is a common and potentially devastating manifestation of SLE. It is a leading cause of morbidity and mortality in patients with SLE. LN leads to inflammation of small blood vessels which play an important role in filtering waste materials in the kidney. It also involves the inflammation of glomeruli.

Although LN can occur during a flare of SLE with skin manifestations or other organ system involvement, it often occurs without other clinical signs of active lupus. Thus, it is of key importance that patients with lupus have routine urine analysis with microscopy looking for protein, blood, and cellular casts. Lupus nephritis is primarily caused by the deposition of immune complexes. The size of the complexes determines the location of deposition, and therefore, leads to differences in classification (mesangial, focal, diffuse).

The launch of the emerging therapies is expected to significantly impact Lupus nephritis treatment scenario in the upcoming years:-
Drugs covered

1. Prograf
2. Obinutuzumab
3. Belimumab
4. Voclosporin
5. Anifrolumab
6. BI 655064
7. Iscalimab

And many others

 

The key players in Lupus nephritis market are:

1. Astellas Pharma
2. Roche
3. GlaxoSmithKline
4. Aurinia Pharmaceuticals
5. AstraZeneca
6. Boehringer Ingelheim
7. Novartis

And many others

 

Request for sample pages : https://delveinsight.com/sample-request/lupus-nephritis-market

Table of contents

1. Key Insights

2. Executive Summary of Lupus Nephritis

3. Competitive Intelligence Analysis for Lupus Nephritis

4. Lupus Nephritis: Market Overview at a Glance

4.1. Lupus Nephritis Total Market Share (%) Distribution in 2017

4.2. Lupus Nephritis Total Market Share (%) Distribution in 2030

5. Lupus Nephritis: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Lupus Nephritis Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Lupus Nephritis Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Lupus Nephritis Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Lupus Nephritis Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Lupus Nephritis Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Lupus Nephritis Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Lupus Nephritis Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Lupus Nephritis Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Lupus Nephritis Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Lupus Nephritis Treatment and Management

8.2. Lupus Nephritis Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Lupus Nephritis Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Lupus Nephritis: Seven Major Market Analysis

13.1. Key Findings

13.2. Lupus Nephritis Market Size in 7MM

13.3. Lupus Nephritis Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Lupus Nephritis Total Market Size in the United States

15.1.2. Lupus Nephritis Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Lupus Nephritis Total Market Size in Germany

15.3.2. Lupus Nephritis Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Lupus Nephritis Total Market Size in France

15.4.2. Lupus Nephritis Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Lupus Nephritis Total Market Size in Italy

15.5.2. Lupus Nephritis Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Lupus Nephritis Total Market Size in Spain

15.6.2. Lupus Nephritis Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Lupus Nephritis Total Market Size in the United Kingdom

15.7.2. Lupus Nephritis Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Lupus Nephritis Total Market Size in Japan

15.8.3. Lupus Nephritis Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Lupus Nephritis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary. 

 

Related Reports:

Lupus Nephritis – Pipeline Insights, 2020

The Dry eye disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Dry eye disease across the complete product development cycle, including all clinical and nonclinical stages.

Lupus Nephritis – Epidemiology Forecast to 2030

The Lupus Nephritis epidemiology covered in the report provides historical as well as forecasted Lupus Nephritis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/